Abstract
Although β2-receceptor agonists are powerful bronchodilators and are at the forefront of asthma symptom relief, patients who use them frequently develop partial resistance to them. This can be a particularly serious problem during severe attacks, where high dose β2-agonist treatment is the front line therapy. Alternative bronchodilators are urgently needed. In this article we review the evidence for the bronchodilator effects of the cannabinoid CB1 receptor tetrahydrocannabinol (THC) and suggest that the mechanisms of action for these effects are sufficiently independent of the mechanisms of standard bronchodilators to warrant clinical investigation. Specifically, clinical trials testing the bronchodilator effects of THC in β2 agonist resistant asthmatic patients would show whether THC could fill the role of rescue bronchodilator in cases of β2 agonist resistance.
Keywords: Asthma, bronchodilation, β2-agonist, CB1 receptor, salbutamol, THC.
Current Drug Targets
Title:The Case for Cannabinoid CB1 Receptors as a Target for Bronchodilator Therapy for β-agonist Resistant Asthma
Volume: 19 Issue: 11
Author(s): John C. Ashton*Robert J. Hancox
Affiliation:
- Department of Pharmacology & Toxicology, Otago School of Biomedical Sciences, University of Otago, Dunedin,New Zealand
Keywords: Asthma, bronchodilation, β2-agonist, CB1 receptor, salbutamol, THC.
Abstract: Although β2-receceptor agonists are powerful bronchodilators and are at the forefront of asthma symptom relief, patients who use them frequently develop partial resistance to them. This can be a particularly serious problem during severe attacks, where high dose β2-agonist treatment is the front line therapy. Alternative bronchodilators are urgently needed. In this article we review the evidence for the bronchodilator effects of the cannabinoid CB1 receptor tetrahydrocannabinol (THC) and suggest that the mechanisms of action for these effects are sufficiently independent of the mechanisms of standard bronchodilators to warrant clinical investigation. Specifically, clinical trials testing the bronchodilator effects of THC in β2 agonist resistant asthmatic patients would show whether THC could fill the role of rescue bronchodilator in cases of β2 agonist resistance.
Export Options
About this article
Cite this article as:
Ashton C. John *, Hancox J. Robert, The Case for Cannabinoid CB1 Receptors as a Target for Bronchodilator Therapy for β-agonist Resistant Asthma, Current Drug Targets 2018; 19 (11) . https://dx.doi.org/10.2174/1389450118666170615101220
DOI https://dx.doi.org/10.2174/1389450118666170615101220 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Drugs as Possible Triggers of Takotsubo Cardiomyopathy: A Comprehensive Literature Search - Update 2015
Current Clinical Pharmacology Emerging Role of Interleukins for the Assessment and Treatment of Liver Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets An Update on Drug Interactions with the Herbal Medicine Ginkgo biloba
Current Drug Metabolism Therapeutic Potential of Vanillin and its Main Metabolites to Regulate the Inflammatory Response and Oxidative Stress
Mini-Reviews in Medicinal Chemistry Structure-Based Discovery of PDEs Inhibitors
Current Topics in Medicinal Chemistry Glucocorticoid Receptors and Bone
Current Pharmaceutical Design Recent Progress in Understanding of Structure, Ligand Interactions and the Mechanism of Activation of the β 2-Adrenergic Receptor
Current Medicinal Chemistry Past, Present and Future of Electroanalytical Sensor for Aspirin, Ibuprofen and Paracetamol Detection
Current Pharmaceutical Analysis Antibiotic Potentiation of Natural Products: A Promising Target to Fight Pathogenic Bacteria
Current Drug Targets Anti-inflammatory Natural Prenylated Phenolic Compounds - Potential Lead Substances
Current Medicinal Chemistry Purinergic Receptors and Pain
Current Pharmaceutical Design Immunomodulatory Actions of Vitamin D Metabolites and their Potential Relevance to Human Lung Disease
Current Respiratory Medicine Reviews Secretory Leukocyte Protease Inhibitor: More than Just A Protease Inhibitor
Current Immunology Reviews (Discontinued) Prevention and Management of Hypertension Without Drugs
Current Hypertension Reviews Nanomedicine against Alzheimer’s and Parkinson’s Disease
Current Pharmaceutical Design Anti-allergic Assessment of Ethanol Extractives of <i>Quisqualis Indica</i> Linn
Current Bioactive Compounds Stable Angina Pectoris: Current Medical Treatment
Current Pharmaceutical Design Oral Agents in Multiple Sclerosis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Influenza Antiviral Therapeutics
Recent Patents on Anti-Infective Drug Discovery TRP Channels in Respiratory Pathophysiology: the Role of Oxidative, Chemical Irritant and Temperature Stimuli
Current Neuropharmacology